**
A growing number of Americans are pursuing legal action against pharmaceutical giants, alleging harmful side effects from popular weight-loss medications. As the use of GLP-1 drugs, such as Wegovy and Ozempic, continues to rise, so too do the complaints surrounding serious health issues, prompting thousands to seek justice for their suffering.
Increasing Use of GLP-1 Medications
Recent estimates from the Kaiser Family Foundation reveal that approximately 12% of the U.S. population is now utilising weight-loss injections, a significant increase in a market that has exploded in popularity. The surge in demand for these medications, typically prescribed for obesity and type 2 diabetes, has coincided with a spike in lawsuits against their manufacturers, Novo Nordisk and Eli Lilly.
Since 2023, around 4,400 individuals have filed claims, with plaintiffs ranging in age from 18 to 87. Reports indicate that roughly 75% of these claimants suffer from gastroparesis, a condition marked by delayed gastric emptying, while 8% report experiencing severe gastrointestinal complications, including uncontrollable vomiting.
Personal Accounts of Adverse Effects
Among the plaintiffs is JoHelen McClain, a 72-year-old real estate agent from Oklahoma City. In March 2024, while driving her granddaughter home, McClain experienced a horrifying incident that led to a hospital visit. She described hearing a loud bang, similar to a balloon bursting, only to find herself diagnosed with a ruptured colon. Her ordeal resulted in a five-day hospital stay, during which she developed sepsis. McClain is now one of many targeting Novo Nordisk in pursuit of accountability.
Similarly, Todd Engel, a 63-year-old machinery operator from Maryland, recounts his harrowing experience after taking Ozempic for diabetes management. In October 2023, Engel suffered an eye stroke, medically known as non-arteritic anterior ischemic optic neuropathy (NAION), leading to significant vision loss. The European product label for Ozempic indicates that this condition may affect up to 1 in 10,000 users.
Pharmaceutical Companies Respond
In response to the mounting lawsuits, both Novo Nordisk and Eli Lilly assert that their medications have undergone comprehensive testing to ensure safety and efficacy. The companies have filed joint court documents outlining their intentions to vigorously defend against the allegations.
“GLP-1 receptor agonists have revolutionised the treatment of obesity and type 2 diabetes,” a company statement emphasised, noting that extensive clinical trials have confirmed their safety profile. They highlighted that the known risks associated with these drugs are clearly detailed in their FDA-approved product labels, which have been reviewed multiple times.
Despite these assurances, the demand for these weight-loss drugs continues to soar. Prescription rates for GLP-1 medications surged from 1 million in early 2018 to a staggering 9 million by 2022. Recent data indicates that the use of Ozempic and Wegovy has doubled between 2024 and 2025, underscoring the growing reliance on these treatments.
Why it Matters
The escalation in lawsuits surrounding GLP-1 weight-loss medications raises critical questions about the balance between effective treatment and patient safety. As more individuals share their distressing experiences, it highlights the urgent need for ongoing scrutiny of pharmaceutical practices and regulatory oversight. The outcome of these legal battles could not only impact the companies involved but may also reshape public perception and trust in weight-loss therapies, ultimately influencing treatment options for millions seeking help in their health journeys.
